World Wires · story 32338 · unverified · 1 source(s)

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Vetera

Open in the desk

Coverage

What this site indexes